Proceedings of the International scientific and practical conference ―Science, technology and cultural innovations‖ (October 7-9, 2025) / Publisher website: www.naukainfo.com. – Vienna, Austria, 2025. - 138 p.

82 REFERENCES 1. Tay CT, Hart RJ, Hickey M, et al. Updated adolescent diagnostic criteria for polycystic ovary syndrome: impact on prevalence and longitudinal body mass index trajectories from birth to adulthood. BMC Med 2020;18:389 2. Visniauskas B, Kilanowski-Doroh I, Ogola BO, Mcnally AB, Horton AC, Imulinde Sugi A, Lindsey SH. Estrogen-mediated mechanisms in hypertension and other cardiovascular diseases. J Hum Hypertens. 2023 Aug;37(8):609-618. doi: 10.1038/s41371-022-00771-0 3. International Evidence-based Guideline for the assessment and management of polycystic ovary syndrome / Society of Endocrinology and the European Society of Human Reproduction and Embryology 2023;295р 4. Bidstrup H, Brennan L, Kaufmann L, de la Piedad Garcia X. Internalised weight stigma as a mediator of the relationship between experienced/perceived weight stigma and biopsychosocial outcomes: a systematic review. Int J Obes (Lond) 2022;46:1-9 5. Горбатюк О.Г. Григоренко А.П., Васьків О.В. Методика профілактичного лікування дівчат підліткового віку з підвищеним ризиком синдрому полікистозних яєчників: свідоцтво про реєстрацію авторського права на твір № 137323; заявка с202504249 від 07.05.2025; зареєстр. 24.06.2025. 6. Inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: now and the future. Laganà AS, Myers SH, Forte G, Naem A, Krentel H, Allahqoli L, Alkatout I, Unfer V.Expert Opin Drug Metab Toxicol. 2024 Jan-Feb;20(1-2):61-72. doi: 10.1080/17425255.2024.2306851. 7. Gabbard RD, Hoopes RR, Kemp MG. Spironolactone and XPB: An Old Drug with a New Molecular Target. Biomolecules. 2020 May 13;10(5):756. doi: 10.3390/biom10050756